BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

AffaMed Therapeutics Approved for Phase 3 Trial of DEXTENZA® in China for Eye Surgery Inflammation and Pain

In addition, AffaMed is pleased to announce that DEXTENZA has recently been approved in Macau, China for the treatment of ocular itchin...

April 17, 2023 | News

Minghui Pharma's MH004 Cream Succeeds in Phase 2 Trial for Atopic Dermatitis, Global Phase 3 MRCT Cleared by FDA

Study met both primary and all key secondary endpoints Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in...

April 14, 2023 | News

Zenshine's ZX-7101A meets primary endpoint in Phase 2 flu treatment study

Interim analysis of the phase 2 cohort of ZX-7101A phase 2/3 adaptive design pivotal study (registration number: CTR20221729), a multicenter, randomized, d...

April 14, 2023 | News

Bone Biologics Gets Approval for Pilot Clinical Trial with NB1 for Spinal Fusion in Australia.

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces that the Human Research Ethics Committ...

April 13, 2023 | News

Bridge Bio Announces First Patient Dosed in Phase 2a Trial of BBT-877 for Idiopathic Pulmonary Fibrosis Treatment

In the Phase 1 study in 2019, BBT-877, a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as...

April 13, 2023 | News

Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bioph...

April 13, 2023 | News

Genexine's GX-E4 Phase 3 trial shows non-inferiority to Mircera for anemia treatment, presented at WCN2023

Kidneys are responsible for 90% of the EPO produced in our bodies. CKD-induced anemia is caused by the failure to produce EPO (erythropoietin) due to long-...

April 12, 2023 | News

Evopoint, MSD Partner for Clinical Trial of XNW5004 with KEYTRUDA in Solid Tumors.

XNW5004 is a rationally designed, highly selective and potent EZH2 inhibitor with potentially best-in-class efficacy and safety profile demonstrated in a P...

April 10, 2023 | News

First patient dosed in China Phase III trial for COPD, announces Nuance Pharma

Ensifentrine is a first-in-class, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and non-s...

April 07, 2023 | News

Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis

"BSI-045B is a next generation anti-TSLP mAb with high affinity and bioactivity that has the potential to offer greater therapeutic potential for patients ...

April 05, 2023 | News

Suvoda Unveils New Brand to Reflect Expanded Focus in Complex Clinical Trial Management

Suvoda LLC in March month, launched a refreshed brand, to better reflect its leadership position as a global clinical trial technology company t...

April 04, 2023 | News

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

LNK01003 is an oral small molecule JAK inhibitor with intestine-restricted properties developed by the company for the treatment of ulcerative colitis and ...

April 04, 2023 | News

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model

According to the company's explanation, bacteriophages have been mainly used for R&D on bacterial infectious diseases, but recently the scope of applic...

April 04, 2023 | News

Ablaze Pharmaceuticals to Develop GPC3 Targeted Therapy for Liver Cancer in China

The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...

March 31, 2023 | News

Stay Connected